4.880 s

-0.150 (-2.98%)
Range 4.860 - 5.040   (3.70%)
Open 5.010
Previous Close 5.030
Buy Price 3.800
Buy Volume 47,100
Sell Price 3.810
Sell Volume 76,900
Volume 216,630
Value -
Remark s
Measurement Type Value
Trailing EPS (USD) -0.137
Cash In Hand (USD) 0.325
Dividend -
Dividend Yield (%) -
PE -
Trailing PE -
Price / NAV -
Price / Cash In Hand 16.323
Issued & Paid-up Shares 11,515,000
Treasury Shares -
Market Cap (M) 334.912
Par Value (USD) n.a.
Beta - 75 Days -
R-Squared - 75 Days(%) -
Beta - 500 Days -
R-Squared - 500 Days(%) -
Under CPF Investment Scheme (CPFIS) No
Index Components
Delayed prices. Updated at 16 Oct 2021 04:00.
Data powered by
View All Events


NanoViricides, Inc.is a development-stage company. The Company is a nano-biopharmaceutical (nanomedicine) company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections. The Company has several drugs in various stages of early development. The Company�s drugs are based on several patents, patent applications, provisional patent applications, and other property held by TheraCour Pharma, Inc. (TheraCou), to which the Company has exclusive licenses in perpetuity for the treatment of human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Influenza including Asian Bird Flu Virus (INF), Herpes Simplex Virus (HSV), Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), and Rabies. In September 2011, NanoViricides Inc's Inno-Haven LLC acquired a light industrial building.

Loading Chart...